Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.54 |
| ▸ | PRKAB2 | O43741 | 8/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 8/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 8/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 8/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 8/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 8/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416712 | 0.82 | F7 (0.54) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL23623627 | 0.82 | F7 (0.54) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL12748347 | 0.82 | CYP1A2 (0.57) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL20605026 | 0.79 | MYC (0.47) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL31375034 | 0.76 | F7 (0.51) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL17417760 | 0.75 | KCNH2 (0.52) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL2036977 | 0.71 | NR4A2 (0.69) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL31542356 | 0.71 | NR4A2 (0.69) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL12748348 | 0.71 | CSNK2A2 (0.60) | CSNK2A2CSNK2BCSNK2A1PRKAB2PRKAG1 | |
| SCHEMBL27601872 | 0.71 | MAPT (0.39) | CSNK2A2CSNK2BCSNK2A1NR4A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | ASTELLAS PHARMA INC. | 2011-03-24 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855225-B2 | 17βHSD type 5 inhibitor | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1990335-A1 | 17 BETA HSD TYPE 5 INHIBITOR | Astellas Pharma Inc. (JP) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071146-A1 | 17BetaHSD Type 5 Inhibitor | CYP17A1, HSD17B3, HSD3B1 | CSNK2A2 2109/4885CSNK2B 1590/4885CSNK2A1 1803/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | CSNK2A2 1852/4885CSNK2B 1468/4885CSNK2A1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.